FDA Releases Final Guidance on Quantitative Efficacy and Risk Information in Direct-to-Consumer Promotional Labeling and Advertisements | Sheppard Mullin Richter & Hampton LLP

On June 27, 2023, the Food and Drug Administration (FDA) issued its final guidance for the presentation of “Quantitative Efficacy and Risk Information” in direct-to-consumer (DTC)...

Related Keywords

,Sheppard Mullin Richter Hampton ,Prescription Drug Promotion On Television ,Study Of Oncology Indications In Television Advertising ,See Us Food Drug Administration ,See Untitled Letter To Xeris Pharmaceuticals ,Publication Office Of Prescription Drug Promotion ,Xeris Pharmaceuticals ,Promotional Communications ,Research Pending Peer ,Drug Administration ,Sheppard Mullin Richter ,Use Whole Numbers ,Dont Minimize ,Promotional Communication ,Visual Aids ,Drug Admin ,Presenting Quantitative Efficacy ,Risk Information ,Promotional Labeling ,Advertisements Guidance ,Untitled Letter ,Untitled Letter Recorlev ,Quantitative Efficacy ,Risk Information Guidance ,Social Media Platforms ,Character Space Limitations ,Presenting Risk ,Benefit Information ,Prescription Drugs ,Medical Devices ,Draft Guidance ,Disease Awareness ,Prescription Drug Promotion ,Experimental Study ,Oncology Indications ,Direct To Consumer Television Advertising ,Research Pending Peer Review ,